论文部分内容阅读
肠易激综合症(IBS)系一种生物-心理-社会病症,是一种以腹痛或腹部不适伴排便习惯改变为特征的功能性肠病,目前发病机制不清,据认为肠道感染后和精神心理障碍是 IBS 发病的重要因素。对 IBS 治疗方法的选择均为经验性的,尚无一种方法或药物对所有的患者有肯定的疗效。基于此,本文探讨药物丽珠肠乐与思密达联用治疗腹泻型 IBS,取得了良好的效果。1 资料与方法1.1 病例选择 2003年8月～2005年8月在本院住院及急诊收治的腹泻型 IBS 98例,诊断全部符合1999年罗马会议修订的罗马Ⅱ诊断标准,并排除急性肠炎、慢性细菌性痢疾、乳糖不耐受等病史。其中男40例,女58例,年龄18～42岁,中位年龄30岁,病程6～24个月,平均12.5个月。随机分为联用治疗组33例,男13例,女20例,年龄18～40
Irritable Bowel Syndrome (IBS) is a bio-psycho-social disorder that is a functional bowel disease characterized by changes in abdominal pain or abdominal discomfort with bowel habits. Currently, the pathogenesis is unclear. It is thought that post-intestinal infection And mental disorders are an important factor in the pathogenesis of IBS. The choice of treatment for IBS is empirical and no method or medication has a definite effect on all patients. Based on this, this article discusses the drug Lizhu intestinal music and Smecta combined treatment of diarrhea-type IBS, and achieved good results. 1 Materials and Methods 1.1 Case Selection In our hospital from August 2003 to August 2005 in our hospital and emergency treatment of diarrhea type IBS 98 cases, all diagnosed in line with the 1999 Rome meeting revised Rome II diagnostic criteria and exclude acute enteritis, chronic Bacillary dysentery, lactose intolerance and other medical history. Including 40 males and 58 females, aged 18 to 42 years, the median age of 30 years old, duration of 6 to 24 months, an average of 12.5 months. Randomly divided into combined treatment group of 33 patients, 13 males and 20 females, aged 18 to 40